Evidence map›Paper›PMID 33869057›Full record

ArticleFrontiers in oncology2021

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study.

Qing Chang, Huiping Qiang, Jialin Qian, Yuqiong Lei, Jiahuan Lu, Hui Feng, Yiming Zhao, Baohui Han, Yanwei Zhang, Tianqing Chu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. [Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Qing ChangDepartment of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Huiping QiangDepartment of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Jialin QianDepartment of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Yuqiong LeiDepartment of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Jiahuan LuDepartment of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Hui FengDepartment of Emergency, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Yiming ZhaoDepartment of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Baohui HanDepartment of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Yanwei ZhangDepartment of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Tianqing ChuDepartment of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Shanghai Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe frequency of epidermal growth factor receptor (EGFR) mutations and the efficacy of tyrosine kinase inhibitor (TKI) in Chinese female patients with lung squamous cell carcinoma (SCC) are unknown. This study was designed to investigate the incidence of EGFR mutations and the role of targeted therapy in advanced Chinese female lung SCC patients.

methodsAdvanced female patients diagnosed with lung SCC at the Shanghai Chest Hospital between January 2013 and December 2018 were retrospectively analyzed.

resultsA total of 4223 advanced lung SCC patients were screened, and there were 154 female lung SCC patients who had underwent EGFR mutation detection. Positive EGFR mutations were found in 29.9% (46/154) of female lung SCC patients, including twenty-three 19del mutation (14.9%), twenty-one 21L858R mutation (13.6%) and other mutations (1.4%, 21861Q and 20ins). For 45 EGFR positive mutation female SCC patients, the median progression-free survival (PFS) of patients who received EGFR-TKI therapy (n=38) was 8.0 months (95% CI, 5.4-10.7 months), which was significantly longer than patients who were treated with chemotherapy (8.0 vs. 3.2 months, p=0.024), and the median overall survival (OS) was also longer (24.9 months vs. 13.9 months, p=0.020). The objective response rate (ORR) was 44.7% (17/38), and the disease control rate (DCR) was 81.6% (31/38). For 105 female SCC patients with EGFR negative mutation, the median OS was 18.6 months (95% CI, 14.2-22.9 months) and it was no different from that of EGFR positive mutation patients (18.6 vs. 22.8 months, p=0.377).

conclusionFor advanced Chinese female lung SCC patients with EGFR positive mutations, targeted therapy could confer longer PFS and OS than chemotherapy, but the survival was similar with patients who were negative EGFR mutations.

Indexed as

epidermal growth factor receptorfemalelung cancersquamous cell carcinomatyrosine kinase inhibitor

Identifiers

PMID33869057
PMCPMC8050333
OpenAlexW3143307513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.